FYERS
Home
/
Stocks
/
Results
/
Akums Drugs & Pharmaceuticals Results

Akums Drugs & Pharmaceuticals Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
10%10%6%6%
15%16%39%-25%
---65%
6%2%9%8%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
AKUMS
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,907.3₹456833 Cr37.7712.0762.82₹11479 Cr
9,155₹245426 Cr83.9134.04128.41₹2568 Cr
4,901.5₹187320 Cr85.8916.7297.06₹2163 Cr
1,128.4₹113217 Cr25.099.4262.53₹5040 Cr
1,381.5₹112212 Cr33.299.7757.87₹3879 Cr
1,854.7₹101155 Cr92.526.829.25₹889 Cr
2,123₹97626 Cr17.6630.95154.36₹5333 Cr
2,360.3₹96859 Cr47.4213.7571.08₹1913 Cr
1,157.8₹96406 Cr29.925.3263.99₹4196 Cr
1,629.3₹93614 Cr25.2217.9596.84₹3505 Cr
752.1₹12300 Cr42.166.5328.62₹255 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
₹1167 Cr₹1158 Cr₹1160 Cr₹1018 Cr₹1024 Cr₹1056 Cr₹1010 Cr₹1033 Cr₹1019 Cr₹944 Cr₹1083 Cr₹1181 Cr₹970 Cr
₹30 Cr₹35 Cr₹34 Cr₹32 Cr₹27 Cr₹18 Cr₹15 Cr₹13 Cr₹7 Cr₹10 Cr₹9 Cr₹7 Cr₹8 Cr
₹1197 Cr₹1193 Cr₹1194 Cr₹1050 Cr₹1051 Cr₹1073 Cr₹1025 Cr₹1047 Cr₹1026 Cr₹954 Cr₹1092 Cr₹1188 Cr₹978 Cr
₹1033 Cr₹1046 Cr₹1052 Cr₹961 Cr₹932 Cr₹1002 Cr₹934 Cr₹947 Cr₹925 Cr₹975 Cr₹1021 Cr₹1060 Cr₹1125 Cr
₹205 Cr₹187 Cr₹181 Cr₹127 Cr₹156 Cr₹111 Cr₹136 Cr₹135 Cr₹135 Cr₹13 Cr₹102 Cr₹159 Cr-₹117 Cr
₹25 Cr₹24 Cr₹24 Cr₹23 Cr₹23 Cr₹5 Cr₹5 Cr₹12 Cr₹13 Cr₹12 Cr₹12 Cr₹14 Cr₹12 Cr
₹139 Cr₹121 Cr₹100 Cr₹66 Cr₹96 Cr₹75 Cr₹91 Cr₹92 Cr₹87 Cr-₹33 Cr₹59 Cr₹87 Cr-₹159 Cr
₹101 Cr₹81 Cr₹68 Cr₹43 Cr₹65 Cr₹150 Cr₹66 Cr₹67 Cr₹61 Cr-₹39 Cr₹195 Cr₹33 Cr-₹187 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014
—————————————
₹31 Cr₹31 Cr₹29 Cr₹29 Cr₹14 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr
₹3283 Cr₹3016 Cr₹681 Cr₹689 Cr₹608 Cr₹884 Cr₹721 Cr₹855 Cr₹794 Cr₹710 Cr₹628 Cr₹493 Cr₹457 Cr
₹3283 Cr₹3016 Cr₹681 Cr₹689 Cr₹608 Cr₹884 Cr₹721 Cr₹855 Cr₹794 Cr₹710 Cr₹628 Cr₹493 Cr₹457 Cr
₹3313 Cr₹3047 Cr₹709 Cr₹717 Cr₹622 Cr₹885 Cr₹722 Cr₹856 Cr₹795 Cr₹711 Cr₹629 Cr₹494 Cr₹458 Cr
₹18 Cr₹17 Cr₹11 Cr₹6 Cr₹3 Cr₹2 Cr-₹2 Cr₹35 Cr₹29 Cr₹21 Cr₹12 Cr₹3 Cr₹1 Cr
₹0₹0₹78 Cr₹115 Cr₹13 Cr₹0₹10 Cr₹45 Cr₹17 Cr₹0₹52 Cr₹78 Cr₹18 Cr
₹0₹0₹0₹0₹0₹1 Cr₹0₹0₹0₹0₹6 L₹0₹0
-₹153 Cr-₹189 Cr-₹111 Cr-₹6 Cr₹20 Cr₹27 Cr₹33 Cr₹35 Cr₹34 Cr₹21 Cr₹39 Cr₹25 Cr₹25 Cr
₹955 Cr₹102 Cr₹1464 Cr₹1111 Cr₹1095 Cr₹637 Cr₹524 Cr₹12 Cr₹11 Cr₹5 Cr₹6 Cr₹6 Cr₹5 Cr
₹49 Cr₹36 Cr₹31 Cr₹26 Cr₹24 Cr₹20 Cr₹19 Cr₹26 Cr₹25 Cr₹24 Cr₹26 Cr₹23 Cr₹21 Cr
₹850 Cr-₹52 Cr₹1462 Cr₹1246 Cr₹1153 Cr₹685 Cr₹586 Cr₹118 Cr₹85 Cr₹50 Cr₹123 Cr₹133 Cr₹70 Cr
—————————————
₹602 Cr₹643 Cr₹532 Cr₹567 Cr₹590 Cr₹341 Cr₹423 Cr₹210 Cr₹244 Cr₹147 Cr₹151 Cr₹153 Cr₹122 Cr
₹345 Cr₹180 Cr₹253 Cr₹246 Cr₹238 Cr₹84 Cr₹110 Cr₹119 Cr₹85 Cr₹79 Cr₹104 Cr₹83 Cr₹46 Cr
₹73 Cr₹14 Cr₹368 Cr₹388 Cr₹338 Cr₹86 Cr₹130 Cr₹182 Cr₹143 Cr₹183 Cr₹136 Cr₹156 Cr₹139 Cr
₹74 Cr₹58 Cr₹58 Cr₹65 Cr₹107 Cr₹68 Cr₹67 Cr₹14 Cr₹8 Cr₹8 Cr₹7 Cr₹20 Cr₹7 Cr
₹1095 Cr₹894 Cr₹1211 Cr₹1266 Cr₹1272 Cr₹580 Cr₹730 Cr₹525 Cr₹480 Cr₹417 Cr₹396 Cr₹412 Cr₹315 Cr
₹5276 Cr₹3905 Cr₹3393 Cr₹3235 Cr₹3050 Cr₹2152 Cr₹2037 Cr₹1535 Cr₹1389 Cr₹1200 Cr₹1161 Cr₹1042 Cr₹845 Cr
₹99 Cr₹92 Cr₹89 Cr₹82 Cr₹98 Cr₹22 Cr₹20 Cr₹27 Cr₹25 Cr₹13 Cr₹20 Cr₹18 Cr₹15 Cr
₹73 Cr₹14 Cr₹492 Cr₹537 Cr₹358 Cr₹97 Cr₹175 Cr₹269 Cr₹173 Cr₹195 Cr₹213 Cr₹255 Cr₹166 Cr
—————————————
₹2445 Cr₹2252 Cr₹1893 Cr₹1715 Cr₹1542 Cr₹1325 Cr₹992 Cr₹940 Cr₹882 Cr₹784 Cr₹638 Cr₹546 Cr₹376 Cr
₹989 Cr₹854 Cr₹702 Cr₹617 Cr₹521 Cr₹421 Cr₹348 Cr₹288 Cr₹232 Cr₹181 Cr₹137 Cr₹101 Cr₹72 Cr
₹1456 Cr₹1397 Cr₹1191 Cr₹1097 Cr₹1021 Cr₹904 Cr₹644 Cr₹652 Cr₹649 Cr₹603 Cr₹501 Cr₹444 Cr₹304 Cr
₹177 Cr₹160 Cr₹195 Cr₹103 Cr₹31 Cr₹17 Cr₹57 Cr₹0₹0₹0₹7 Cr₹0₹22 Cr
₹14 L₹14 L₹14 L₹14 L₹39 L₹53 L₹56 L₹9 Cr₹12 Cr₹4 L₹18 Cr₹0₹0
₹14 L₹14 L₹14 L₹14 L₹39 L₹53 L₹56 L₹9 Cr₹12 Cr₹4 L₹18 Cr₹0₹0
₹76 Cr₹61 Cr₹56 Cr₹96 Cr₹86 Cr₹44 Cr₹36 Cr₹40 Cr₹26 Cr₹21 Cr₹51 Cr₹37 Cr₹52 Cr
₹7 Cr₹9 Cr₹10 Cr₹14 Cr₹20 Cr₹29 Cr₹50 Cr₹99 L₹51 L₹3 Cr₹0₹0₹0
₹1716 Cr₹1631 Cr₹1452 Cr₹1311 Cr₹1159 Cr₹995 Cr₹787 Cr₹702 Cr₹688 Cr₹626 Cr₹580 Cr₹481 Cr₹378 Cr
—————————————
₹0₹0₹0₹0₹0₹19 Cr₹6 Cr₹0₹0₹0₹0₹0₹0
₹756 Cr₹681 Cr₹630 Cr₹730 Cr₹722 Cr₹430 Cr₹398 Cr₹268 Cr₹295 Cr₹244 Cr₹289 Cr₹261 Cr₹192 Cr
₹797 Cr₹770 Cr₹834 Cr₹845 Cr₹884 Cr₹531 Cr₹582 Cr₹473 Cr₹334 Cr₹295 Cr₹259 Cr₹273 Cr₹241 Cr
₹1681 Cr₹576 Cr₹277 Cr₹150 Cr₹103 Cr₹68 Cr₹147 Cr₹21 Cr₹18 Cr₹7 Cr₹14 Cr₹12 Cr₹24 Cr
₹24 Cr₹32 Cr₹30 Cr₹15 Cr₹9 Cr₹10 Cr₹13 Cr₹8 Cr₹4 Cr₹4 Cr₹6 Cr₹6 Cr₹4 Cr
₹303 Cr₹215 Cr₹169 Cr₹139 Cr₹145 Cr₹99 Cr₹104 Cr₹64 Cr₹49 Cr₹24 Cr₹13 Cr₹10 Cr₹5 Cr
₹3560 Cr₹2275 Cr₹1941 Cr₹1879 Cr₹1864 Cr₹1157 Cr₹1250 Cr₹833 Cr₹701 Cr₹574 Cr₹580 Cr₹561 Cr₹466 Cr
₹2465 Cr₹1381 Cr₹730 Cr₹613 Cr₹592 Cr₹577 Cr₹520 Cr₹308 Cr₹221 Cr₹157 Cr₹184 Cr₹149 Cr₹151 Cr
₹5276 Cr₹3905 Cr₹3393 Cr₹3235 Cr₹3050 Cr₹2152 Cr₹2037 Cr₹1535 Cr₹1389 Cr₹1200 Cr₹1161 Cr₹1042 Cr₹845 Cr
₹216₹199₹50₹50₹87₹6,801₹5,554₹7,286₹6,763₹6,053₹5,356₹4,204₹3,901
₹216₹199₹50₹50₹43₹62₹50₹66₹61₹55₹49₹38₹35

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014
₹382 Cr₹345 Cr-₹45 Cr₹150 Cr-₹193 Cr₹172 Cr₹114 Cr₹126 Cr₹150 Cr₹143 Cr₹89 Cr₹77 Cr₹126 Cr
₹164 Cr₹172 Cr₹556 Cr₹158 Cr₹631 Cr₹144 Cr₹78 Cr₹74 Cr₹68 Cr₹67 Cr₹64 Cr₹59 Cr₹27 Cr
₹722 Cr₹30 Cr₹50 Cr-₹34 Cr-₹352 Cr-₹137 Cr-₹115 Cr-₹172 Cr-₹13 Cr-₹16 Cr-₹11 Cr-₹45 Cr-₹135 Cr
₹1269 Cr₹546 Cr₹561 Cr₹274 Cr₹87 Cr₹179 Cr₹77 Cr₹28 Cr₹204 Cr₹194 Cr₹141 Cr₹90 Cr₹17 Cr
₹1181 Cr₹465 Cr₹498 Cr₹177 Cr₹32 Cr₹134 Cr₹28 Cr-₹23 Cr₹157 Cr₹156 Cr₹89 Cr₹72 Cr-₹15 Cr
-₹930 Cr-₹548 Cr-₹330 Cr-₹305 Cr-₹235 Cr-₹109 Cr-₹190 Cr-₹49 Cr-₹111 Cr-₹128 Cr-₹123 Cr-₹150 Cr-₹55 Cr
₹34 Cr₹73 Cr-₹108 Cr₹125 Cr₹236 Cr-₹95 Cr₹233 Cr₹75 Cr-₹35 Cr-₹34 Cr₹37 Cr₹66 Cr₹89 Cr
₹285 Cr-₹10 Cr₹60 Cr-₹4 Cr₹33 Cr-₹70 Cr₹71 Cr₹3 Cr₹11 Cr-₹7 Cr₹4 Cr-₹11 Cr₹18 Cr
₹101 Cr₹111 Cr₹52 Cr₹55 Cr₹22 Cr₹92 Cr₹21 Cr₹18 Cr₹7 Cr₹14 Cr₹10 Cr₹21 Cr₹3 Cr
₹0₹0-₹38 L₹0₹0₹51 L₹0₹0₹0₹0₹0₹0₹0
₹386 Cr₹101 Cr₹111 Cr₹52 Cr₹55 Cr₹22 Cr₹92 Cr₹21 Cr₹18 Cr₹7 Cr₹14 Cr₹10 Cr₹21 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)784.40
Volume (₹)91,135.00
High (₹)785.00
Upper Circuit858.60
Low (₹)748.35
Lower Circuit702.50
Prev Close780.55
52W High (₹)796.55
Price752.10
52W Low (₹)409.30

Share Market Cap & Key Ratios Overview

M.Cap (₹)12299.60 Cr
Div. Yield (%)0.38
PE Ratio42.16
Debt to Equity0.02
Price to Book2.15
Book Value216.41
EPS (TTM)18.53
Face Value2.00
ROE (%)8.06

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
AKUMSNSE
LTP
1W Low
1W High
Market cap (₹)
1907.3-12.7 (-0.66%)
1905
1984.80
4,56,833Cr
9155-84 (-0.91%)
9087
9467
2,45,426Cr
4901.5-148.5 (-2.94%)
4886.50
5066
1,87,320Cr
1128.4-62.6 (-5.26%)
1128
1187
1,13,217Cr
1381.5-42 (-2.95%)
1381
1426.10
1,12,212Cr
1854.7-83.8 (-4.32%)
1811.70
1949
1,01,155Cr
2123-48.5 (-2.23%)
2123
2192
97,626Cr
2360.3-22.6 (-0.95%)
2341.20
2419.20
96,859Cr
1157.8-20.2 (-1.71%)
1154.40
1179.90
96,406Cr
1629.3-16 (-0.97%)
1626
1717
93,614Cr
752.1-20.5 (-2.65%)
748.35
796.55
12,300Cr

Akums Drugs & Pharmaceuticals Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹205.06Cr; with other income of ₹30.38Cr, profit before interest and tax came to ₹163.99Cr. Interest expense was ₹24.76Cr; PBT before exceptional items stood at ₹139.24Cr. Cost mix (full year): raw materials ₹2499.68Cr; employee cost ₹753.82Cr; depreciation ₹41.06Cr; other expenses ₹991.95Cr. Basis: consolidated annual results.

Akums Drugs & Pharmaceuticals Ltd Quaterly Results Key Takeaways

Akums Drugs & Pharmaceuticals Ltd reported ₹1166.63Cr total income from operations in Jun 2026, softer than ₹1157.87Cr in Mar 2026 but higher than ₹1024.03Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹205.06Cr; with other income of ₹30.38Cr, profit before interest and tax came to ₹163.99Cr. Interest expense was ₹24.76Cr, taking profit before tax to ₹139.24Cr. After tax of ₹38.26Cr, profit after tax stood at ₹100.98Cr (vs ₹81.34Cr in Mar 2026 and ₹64.69Cr in Jun 2025).